Funding round completed
Cell Medica Ltd, an early stage cellular therapy company developing treatments for infectious disease and cancer, has raised £1.95 million in a funding round led by Imperial Innovations Group plc.
Imperial Innovations invested £1.19 million, with the balance coming from existing private investors. Cell Medica has now raised a total of £4.5 million since it was set up in 2007 to commercialise a cell therapy technique that protects patients with weakened immune systems against latent cytomegalovirus infections, particularly after bone marrow transplants.
The company received seed funding from Imperial Innovations and backed by a translational research grant from the Wellcome Trust, to fund a Phase III trial of the therapy, which is in part based on technology developed at Imperial College.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.